Hereditary angioedema

Validation of the end point time to onset of relief by correlation with symptom intensity

Jonathan A. Bernstein, Bruce Ritchie, Robyn J. Levy, Richard L. Wasserman, Againdra K. Bewtra, David S. Hurewitz, Krystyna Obtułowicz, Avner Reshef, Dumitru Moldovan, Todor Shirov, Vesna Grivcheva-Panovska, Peter C. Kiessling, Heinz Otto Keinecke, Timothy J. Craig

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Time to onset of symptom relief in hereditary angioedema (HAE) is a common primary end point in clinical studies but it has never been validated by correlation with the course of HAE symptoms. This study was designed as a retrospective validation of the primary end point for a placebo-controlled phase II/III study in patients with HAE.Ninety-eight abdominal attacks were treated with 10 or 20 U/kg of a highly purified C1 esterase inhibitor (C1-INH) concentrate or placebo. The primary end point was the time to onset of symptom relief, as determined by the patients. Patients assessed the intensity of the symptoms of pain, nausea, vomiting, cramps, and diarrhea over time. By Spearman rank correlation, the primary end point was compared with the time to first reduction of (1) any symptom intensity, (2) the sum of symptom intensity scores, and (3) the intensity of the last symptom present at baseline. The C1-INH, 20 U/kg, and placebo groups were compared by one-sided two-sample Wilcoxon tests. The time to first reduction in intensity of the last symptom present at baseline had the highest correlation with the primary end point (r = 0.77). The time to onset of symptom relief and the time to the first reduction in intensity of the last symptom were significantly shorter for the C1-INH, 20 U/kg, group compared with placebo (p = 0.009 and p = 0.0036, respectively). The association with the intensity of single symptoms confirmed that the time to onset of symptom relief is an appropriate end point for assessing the efficacy of C1-INH therapy.

Original languageEnglish
Pages (from-to)36-42
Number of pages7
JournalAllergy and Asthma Proceedings
Volume32
Issue number1
DOIs
StatePublished - Jan 2011

Fingerprint

Hereditary Angioedemas
Complement C1 Inhibitor Protein
Placebos
Muscle Cramp
Nausea
Vomiting
Diarrhea
Pain

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Pulmonary and Respiratory Medicine

Cite this

Hereditary angioedema : Validation of the end point time to onset of relief by correlation with symptom intensity. / Bernstein, Jonathan A.; Ritchie, Bruce; Levy, Robyn J.; Wasserman, Richard L.; Bewtra, Againdra K.; Hurewitz, David S.; Obtułowicz, Krystyna; Reshef, Avner; Moldovan, Dumitru; Shirov, Todor; Grivcheva-Panovska, Vesna; Kiessling, Peter C.; Keinecke, Heinz Otto; Craig, Timothy J.

In: Allergy and Asthma Proceedings, Vol. 32, No. 1, 01.2011, p. 36-42.

Research output: Contribution to journalArticle

Bernstein, JA, Ritchie, B, Levy, RJ, Wasserman, RL, Bewtra, AK, Hurewitz, DS, Obtułowicz, K, Reshef, A, Moldovan, D, Shirov, T, Grivcheva-Panovska, V, Kiessling, PC, Keinecke, HO & Craig, TJ 2011, 'Hereditary angioedema: Validation of the end point time to onset of relief by correlation with symptom intensity', Allergy and Asthma Proceedings, vol. 32, no. 1, pp. 36-42. https://doi.org/10.2500/aap.2011.32.3404
Bernstein, Jonathan A. ; Ritchie, Bruce ; Levy, Robyn J. ; Wasserman, Richard L. ; Bewtra, Againdra K. ; Hurewitz, David S. ; Obtułowicz, Krystyna ; Reshef, Avner ; Moldovan, Dumitru ; Shirov, Todor ; Grivcheva-Panovska, Vesna ; Kiessling, Peter C. ; Keinecke, Heinz Otto ; Craig, Timothy J. / Hereditary angioedema : Validation of the end point time to onset of relief by correlation with symptom intensity. In: Allergy and Asthma Proceedings. 2011 ; Vol. 32, No. 1. pp. 36-42.
@article{f324dbac9aeb4030a6295d7486982960,
title = "Hereditary angioedema: Validation of the end point time to onset of relief by correlation with symptom intensity",
abstract = "Time to onset of symptom relief in hereditary angioedema (HAE) is a common primary end point in clinical studies but it has never been validated by correlation with the course of HAE symptoms. This study was designed as a retrospective validation of the primary end point for a placebo-controlled phase II/III study in patients with HAE.Ninety-eight abdominal attacks were treated with 10 or 20 U/kg of a highly purified C1 esterase inhibitor (C1-INH) concentrate or placebo. The primary end point was the time to onset of symptom relief, as determined by the patients. Patients assessed the intensity of the symptoms of pain, nausea, vomiting, cramps, and diarrhea over time. By Spearman rank correlation, the primary end point was compared with the time to first reduction of (1) any symptom intensity, (2) the sum of symptom intensity scores, and (3) the intensity of the last symptom present at baseline. The C1-INH, 20 U/kg, and placebo groups were compared by one-sided two-sample Wilcoxon tests. The time to first reduction in intensity of the last symptom present at baseline had the highest correlation with the primary end point (r = 0.77). The time to onset of symptom relief and the time to the first reduction in intensity of the last symptom were significantly shorter for the C1-INH, 20 U/kg, group compared with placebo (p = 0.009 and p = 0.0036, respectively). The association with the intensity of single symptoms confirmed that the time to onset of symptom relief is an appropriate end point for assessing the efficacy of C1-INH therapy.",
author = "Bernstein, {Jonathan A.} and Bruce Ritchie and Levy, {Robyn J.} and Wasserman, {Richard L.} and Bewtra, {Againdra K.} and Hurewitz, {David S.} and Krystyna Obtułowicz and Avner Reshef and Dumitru Moldovan and Todor Shirov and Vesna Grivcheva-Panovska and Kiessling, {Peter C.} and Keinecke, {Heinz Otto} and Craig, {Timothy J.}",
year = "2011",
month = "1",
doi = "10.2500/aap.2011.32.3404",
language = "English",
volume = "32",
pages = "36--42",
journal = "Allergy and Asthma Proceedings",
issn = "1088-5412",
publisher = "OceanSide Publications Inc.",
number = "1",

}

TY - JOUR

T1 - Hereditary angioedema

T2 - Validation of the end point time to onset of relief by correlation with symptom intensity

AU - Bernstein, Jonathan A.

AU - Ritchie, Bruce

AU - Levy, Robyn J.

AU - Wasserman, Richard L.

AU - Bewtra, Againdra K.

AU - Hurewitz, David S.

AU - Obtułowicz, Krystyna

AU - Reshef, Avner

AU - Moldovan, Dumitru

AU - Shirov, Todor

AU - Grivcheva-Panovska, Vesna

AU - Kiessling, Peter C.

AU - Keinecke, Heinz Otto

AU - Craig, Timothy J.

PY - 2011/1

Y1 - 2011/1

N2 - Time to onset of symptom relief in hereditary angioedema (HAE) is a common primary end point in clinical studies but it has never been validated by correlation with the course of HAE symptoms. This study was designed as a retrospective validation of the primary end point for a placebo-controlled phase II/III study in patients with HAE.Ninety-eight abdominal attacks were treated with 10 or 20 U/kg of a highly purified C1 esterase inhibitor (C1-INH) concentrate or placebo. The primary end point was the time to onset of symptom relief, as determined by the patients. Patients assessed the intensity of the symptoms of pain, nausea, vomiting, cramps, and diarrhea over time. By Spearman rank correlation, the primary end point was compared with the time to first reduction of (1) any symptom intensity, (2) the sum of symptom intensity scores, and (3) the intensity of the last symptom present at baseline. The C1-INH, 20 U/kg, and placebo groups were compared by one-sided two-sample Wilcoxon tests. The time to first reduction in intensity of the last symptom present at baseline had the highest correlation with the primary end point (r = 0.77). The time to onset of symptom relief and the time to the first reduction in intensity of the last symptom were significantly shorter for the C1-INH, 20 U/kg, group compared with placebo (p = 0.009 and p = 0.0036, respectively). The association with the intensity of single symptoms confirmed that the time to onset of symptom relief is an appropriate end point for assessing the efficacy of C1-INH therapy.

AB - Time to onset of symptom relief in hereditary angioedema (HAE) is a common primary end point in clinical studies but it has never been validated by correlation with the course of HAE symptoms. This study was designed as a retrospective validation of the primary end point for a placebo-controlled phase II/III study in patients with HAE.Ninety-eight abdominal attacks were treated with 10 or 20 U/kg of a highly purified C1 esterase inhibitor (C1-INH) concentrate or placebo. The primary end point was the time to onset of symptom relief, as determined by the patients. Patients assessed the intensity of the symptoms of pain, nausea, vomiting, cramps, and diarrhea over time. By Spearman rank correlation, the primary end point was compared with the time to first reduction of (1) any symptom intensity, (2) the sum of symptom intensity scores, and (3) the intensity of the last symptom present at baseline. The C1-INH, 20 U/kg, and placebo groups were compared by one-sided two-sample Wilcoxon tests. The time to first reduction in intensity of the last symptom present at baseline had the highest correlation with the primary end point (r = 0.77). The time to onset of symptom relief and the time to the first reduction in intensity of the last symptom were significantly shorter for the C1-INH, 20 U/kg, group compared with placebo (p = 0.009 and p = 0.0036, respectively). The association with the intensity of single symptoms confirmed that the time to onset of symptom relief is an appropriate end point for assessing the efficacy of C1-INH therapy.

UR - http://www.scopus.com/inward/record.url?scp=79551490988&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79551490988&partnerID=8YFLogxK

U2 - 10.2500/aap.2011.32.3404

DO - 10.2500/aap.2011.32.3404

M3 - Article

VL - 32

SP - 36

EP - 42

JO - Allergy and Asthma Proceedings

JF - Allergy and Asthma Proceedings

SN - 1088-5412

IS - 1

ER -